Table 1 Baseline demographic and clinical data

no. of patients

118

13

sex (M:F)

80:38

6:7

p < 0.0001 ^a

age (years)

59.6 (53.5–66.7)

62.5 (51.3–70.9)

p = 0.852 ^b

blood pressure (mmHg)

 systolic

138 (123–151)

129 (109–153)

 diastolic

76 (67–85)

72 (64–77)

serum creatinine (µmol/l)

163 (122–255)

225 (103–414)

p = 0.143 ^b

eGFR (ml/min/1.73m²)

37.7 (19.9–52.0)

24.9 (10.8–48.0)

p < 0.0001 ^b

proteinuria (g/day)

2.5 (1.7–4.6)

0.6 (0.3–3.5)

p = 0.011^b

CKD stage, no. of case (%)

p = 0.390

 G1

5 (4.2%)

0

 G2

12 (10.2%)

2 (15.4%)

 G3a

26 922.0%)

1 (7.7%)

 G3b

28 (23.7%)

2 (15.4%)

 G4

27 (22.9%)

3 (23.1%)

 G5

20 (16.9%)

5 (38.5%)

albuminuria stage, no. of case (%)

p < 0.0001

 A1

11 (9.9%)

8 (61.5%)

 A2

59 (53.2%)

2 (15.4%)

 A3

48 (40.7%)

3 (23.1%)

histological damage (%)

 glomerulosclerosis

30.0 (16.7–45.3)

27.8 (18.2–51.4)

p = 0.036 ^b

 tubulointerstitial fibrosis

30.0 (15.0–47.5)

25.0 (10.0–50.0)

p = 0.577 ^b